Chemical formula: C₁₃H₁₄Cl₂O₃ Molecular mass: 289.15 g/mol
Ciprofibrate is a new derivative of phenoxyisobutyric acid which has a marked hypolipidaemic action. It reduces both LDL and VLDL and hence the levels of triglyceride and cholesterol associated with these lipoprotein fractions. It also increases levels of HDL cholesterol.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C10AB08 | Ciprofibrate | C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AB Fibrates |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| CIPROFIBRATE Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| MODALIM Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Ciprofibrate is an active ingredient of these brands:
Ecuador (EC)Estonia (EE)France (FR)Israel (IL)Mexico (MX)Netherlands (NL)Poland (PL)Singapore (SG)Tunisia (TN)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
